SPARK TEL AVIV Selects Two New Projects for the 2026-2027 Program

Novel Therapeutics Track

Third Generation Antifungal Drugs of the Echinocandin Class to Overcome Resistance in Invasive Candidiasis

Principal Investigators

• Prof. Micha Fridman, School of Chemistry, Tel Aviv University
• Prof. Ronen Ben-Ami, Head of the Department of Infectious Diseases, Tel Aviv Sourasky Medical Center

Drug Repurposing Track

Intranasal Delivery of the CCR5 Antagonist Maraviroc: A Novel Strategy for Efficient Treatment of Post-Stroke Cognitive Impairment

Principal Investigators

• Prof. Pablo Blinder, School of Neurobiology, Biochemistry and Biophysics, Tel Aviv University
• Dr. Einor Ben Assayag, Stroke and Dementia Research Group, Tel Aviv Sourasky Medical Center
• Prof. Hen Hallevi, Department of Neurology-Stroke, Tel Aviv Sourasky Medical Center
• Dr. Jeremy Molad, Department of Neurology-Stroke, Tel Aviv Sourasky Medical Center
• Dr. Oren Tene, Psychiatric Division, Tel Aviv Sourasky Medical Center

Congratulations to the selected teams, and welcome to the SPARK TEL AVIV family!